Zimmer Biomet launches TLIF cage for minimally invasive surgery

Zimmer Biomet Holdings Inc. has announced the U.S. launch of the Avenue T TLIF Cage, which is a cage for transforaminal lumbar interbody fusion, according to a company release.

The Avenue T TLIF Cage incorporates VerteBRIDGE plating, which allows for simplified cage insertion, a zero-profile and intradiscal fixation through a direct, minimally invasive surgical approach. According to the release, the Avenue T cage is reportedly the first posteriorly implanted cage for transforaminal lumbar interbody fusion (TLIF) with integrated, antimigration fixation.

According to the release, the system is intended for intervertebral body fusion of the lumbar spine from L2 to S1 in skeletally mature patients following 6 months of nonoperative treatment. The Avenue T cage is indicated for use at either one level or two contiguous levels to treat degenerative disc disease with grade 1 spondylolisthesis or retrolisthesis. The device is intended to be used with or without integrated fixation and must be used in combination with the FDA-cleared supplemental fixation.

Implantation of the Avenue T TLIF cage is via a transforaminal approach and is intended to be used with autograft to enhance fusion.

Reference: